Open an account

CNS Pharmaceuticals

CNSP · NASDAQ

$4.99−$0.01 (−0.20%)TodayMarket closed ·
Prev close $5.00

About CNSP

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 8 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.

Employees
5
Headquarters
Houston, Texas
Listed
Nov 8, 2019
Sector
Health Care
Industry
Pharmaceuticals
Website
cnspharma.com

CNSP key statistics

Market cap
7.29M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
4.29K
Volume
791
Open price
$4.74
High today
$5.00
Low today
$4.76
52 Week high
$10.54
52 Week low
$1.90

CNS Pharmaceuticals (CNSP) at a glance

As of Oct 20, 2026, CNS Pharmaceuticals (CNSP) shares are priced at $4.99, giving the company a market cap of 7.29M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.76 and $5.00. The current price is 4.9% above the day's low and 0.2% below its high.

Volume so far is 791 shares, below the average of 4.29K shares a day.

Over the past year CNS Pharmaceuticals has ranged from $1.90 to $10.54, and now sits 36% of the way up that range.

CNS Pharmaceuticals met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.38 per share against an estimate of -$0.2448.

CNSP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 20.3% on average.

  1. Q3 FY23: reported -$1.08 per share against an estimate of $0.00
  2. Q3 FY24: reported -$150.00 per share against an estimate of -$61.20
  3. Q4 FY24: reported -$111.00 per share against an estimate of -$118.24
  4. Q2 FY25: reported -$6.42 per share against an estimate of -$9.79
  5. Q3 FY25: reported -$5.76 per share against an estimate of -$7.24
  6. Q4 FY25: reported -$10.15 per share against an estimate of -$5.19
  7. Q1 FY26: reported -$7.30 per share against an estimate of -$5.48
  8. Q2 FY26: reported -$0.38 per share against an estimate of -$0.2448

CNSP news

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Vandana Singh

    What's Going On With CNS Pharmaceuticals Stock On Wednesday?

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Avi Kapoor

    Gold Falls Over 2%; US Factory Orders Rise In March

  • Avi Kapoor

    Dow Falls Over 150 Points; Tyson Foods Posts Upbeat Earnings

  • Vandana Singh

    Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot

  • Market-Moving News for May 4th

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Similar companies

Companies in the same industry as CNS Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.